TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive A Take-Home Message From ASCO 2014: NCI-Funded Clinical Research In Jeopardy,bSociety Focuses on Value of NCTN Groups June 6, 2014
TCL Archive Gloom and Doom Meeting of docs Turns Hopeful When Patient Offers Health Reform Proposal February 5, 1993
